Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Trastuzumab Deruxtecan for Patients With HER2-Low Metastatic Breast Cancer

Xichun Hu, MD, PhD

 

Xichun Hu, MD, PhD, Fudan University Cancer Institute, Shangai, China, discussed results from the DESTINY-Breast06 trial which identified trastuzumab deruxtecan as a potential new standard of care for patients with HER2-Low metastatic breast cancer who previously underwent endocrine therapy. 


Source: 

Curigliano G. Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). Presented at the ASCO Annual Meeting. May 31 – June 4, 2024; Chicago, IL. Abstract LBA1000 

© 2024 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates. 

Advertisement

Advertisement

Advertisement

Advertisement